According to Entrada Therapeutics’ announcement, “2026 will be a data-rich year for Duchenne muscular dystrophy; data from the first cohort of ELEVATE-44-201 is expected to be released in the second quarter of 2026, and data from ELEVATE-45-201 in mid-2026.”
- ELEVATE-44-201: The Company completed dosing of Cohort 1 of the global Phase 1/2 multiple ascending dose (MAD) portion of the clinical study of ENTR-601-44 in ambulatory patients living with DMD who are amenable to exon 44 skipping, and transitioned to the open label, Phase 2 portion of the study. The Company is on track to report data from Cohort 1 (6 mg/kg) in the second quarter of 2026, data from Cohort 2 (up to 12 mg/kg) by year-end, and data from Cohort 3 (up to 18 mg/kg) to follow. In December 2025, the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to ENTR-601-44. Learn More: Deletions Amenable to Exon 44 Skipping Therapies
- ELEVATE-44-102: The Company expects to initiate a Phase 1b MAD clinical study of ENTR-601-44 in ambulatory and non-ambulatory adults living with DMD in the U.S. in the first half of 2026.
- ELEVATE-45-201: The Company initiated patient dosing in the global Phase 1/2 MAD portion of the clinical study of ENTR-601-45 in ambulatory patients living with DMD who are amenable to exon 45 skipping. The Company is on track to report data from Cohort 1 (5 mg/kg) in mid-2026, with data from Cohort 2 and Cohort 3 (up to 10 mg/kg and 15 mg/kg) to follow. Learn More: Which Mutations are Amenable to Exon 45 Skipping?
- ELEVATE-50-201: The Company received regulatory authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate a Phase 1/2 MAD clinical study of ENTR-601-50 in ambulatory patients living with DMD who are amenable to exon 50 skipping. The Company expects to submit regulatory applications in the EU for ENTR-601-50 in the second half of 2026 and initiate the study by the end of 2026. Learn More: Deletions Amenable to Exon 50 Skipping Therapies
- ENTR-601-51: The Company expects to submit global regulatory applications for ENTR-601-51 in 2026. Learn More: Deletions Amenable to Exon 51 Skipping Therapies
Read More: Clinical Trials for Duchenne (List of All Researches)
- Follow Us -
